AC Immune 将来の成長

Future 基準チェック /56

AC Immuneは、54.7%と32%でそれぞれ年率54.7%で利益と収益が成長すると予測される一方、EPSはgrowで55.4%年率。

主要情報

54.7%

収益成長率

55.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	32.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Nov 2024

今後の成長に関する最新情報

Recent updates

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

業績と収益の成長予測

NasdaqGM:ACIU - アナリストの将来予測と過去の財務データ ( )CHF Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	67	-27	50	-79	3
12/31/2025	62	-23	25	28	4
12/31/2024	27	-53	-57	33	3
9/30/2024	41	-40	43	44	N/A
6/30/2024	15	-61	44	45	N/A
3/31/2024	15	-55	-43	-43	N/A
12/31/2023	15	-54	-61	-60	N/A
9/30/2023	0	-68	-62	-62	N/A
6/30/2023	4	-67	-62	-62	N/A
3/31/2023	4	-69	-68	-67	N/A
12/31/2022	4	-71	-75	-74	N/A
9/30/2022	4	-73	-76	-74	N/A
6/30/2022	N/A	-76	-77	-75	N/A
3/31/2022	N/A	-75	-74	-71	N/A
12/31/2021	N/A	-73	-68	-66	N/A
9/30/2021	1	-71	-70	-67	N/A
6/30/2021	2	-74	-71	-68	N/A
3/31/2021	3	-71	-69	-67	N/A
12/31/2020	15	-62	-61	-60	N/A
9/30/2020	15	-62	-54	-53	N/A
6/30/2020	47	-25	-22	-20	N/A
3/31/2020	48	-26	-22	-20	N/A
12/31/2019	110	45	53	55	N/A
9/30/2019	111	50	55	56	N/A
6/30/2019	80	18	26	27	N/A
3/31/2019	81	24	34	35	N/A
12/31/2018	7	-51	-46	-44	N/A
9/30/2018	22	-32	-28	-26	N/A
6/30/2018	21	-27	N/A	-22	N/A
3/31/2018	20	-29	N/A	-24	N/A
12/31/2017	20	-26	N/A	-22	N/A
9/30/2017	5	-35	N/A	-35	N/A
6/30/2017	6	-36	N/A	-19	N/A
3/31/2017	25	-10	N/A	-10	N/A
12/31/2016	23	-7	N/A	-6	N/A
9/30/2016	22	-8	N/A	-4	N/A
6/30/2016	45	21	N/A	21	N/A
3/31/2016	39	17	N/A	16	N/A
12/31/2015	39	20	N/A	44	N/A
9/30/2015	65	46	N/A	45	N/A
6/30/2015	41	21	N/A	8	N/A
3/31/2015	28	10	N/A	7	N/A
12/31/2014	30	11	N/A	-18	N/A
12/31/2013	9	-11	N/A	-20	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACIUは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ACIU今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ACIU今後 3 年以内に収益を上げることが予想されます。

収益対市場: ACIUの収益 ( 32% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACIUの収益 ( 32% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACIUの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AC Immune 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

Consensus revenue estimates fall by 55%

Consensus revenue estimates fall by 57%

Consensus revenue estimates fall by 58%

Consensus forecasts updated

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Consensus forecasts updated

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

AC Immune SA, Annual General Meeting, Mar 31, 2021

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study